Thus, rebalancing the TGF-β/Smad signaling by targeting Smad3 activity, up-regulating Smad7, as well as specifically modulating Smad3-dependent miRNAs related to fibrosis may represent an effective therapy for CKD associated with progressive real fibrosis. Here, SMAD3 is linked to chronic kidney disease.